These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 18384181)

  • 1. In vivo MRS markers of response to CHOP chemotherapy in the WSU-DLCL2 human diffuse large B-cell lymphoma xenograft.
    Lee SC; Huang MQ; Nelson DS; Pickup S; Wehrli S; Adegbola O; Poptani H; Delikatny EJ; Glickson JD
    NMR Biomed; 2008 Aug; 21(7):723-33. PubMed ID: 18384181
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo monitoring response to chemotherapy of human diffuse large B-cell lymphoma xenografts in SCID mice by 1H and 31P MRS.
    Huang MQ; Nelson DS; Pickup S; Qiao H; Delikatny EJ; Poptani H; Glickson JD
    Acad Radiol; 2007 Dec; 14(12):1531-9. PubMed ID: 18035282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo (1)H MRS of WSU-DLCL2 human non-Hodgkin's lymphoma xenografts: response to rituximab and rituximab plus CHOP.
    Lee SC; Delikatny EJ; Poptani H; Pickup S; Glickson JD
    NMR Biomed; 2009 Apr; 22(3):259-65. PubMed ID: 19040203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NMR metabolic and physiological markers of therapeutic response.
    Lee SC; Poptani H; Delikatny EJ; Pickup S; Nelson DS; Schuster SJ; Nasta SD; Svoboda J; Goldstein SC; Wallace SG; Loevner LA; Mellon EA; Reddy R; Glickson JD
    Adv Exp Med Biol; 2011; 701():129-35. PubMed ID: 21445779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The addition of bryostatin 1 to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy improves response in a CHOP-resistant human diffuse large cell lymphoma xenograft model.
    Mohammad RM; Wall NR; Dutcher JA; Al-Katib AM
    Clin Cancer Res; 2000 Dec; 6(12):4950-6. PubMed ID: 11156256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Superior antitumor activity of SAR3419 to rituximab in xenograft models for non-Hodgkin's lymphoma.
    Al-Katib AM; Aboukameel A; Mohammad R; Bissery MC; Zuany-Amorim C
    Clin Cancer Res; 2009 Jun; 15(12):4038-45. PubMed ID: 19509168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genistein sensitizes diffuse large cell lymphoma to CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy.
    Mohammad RM; Al-Katib A; Aboukameel A; Doerge DR; Sarkar F; Kucuk O
    Mol Cancer Ther; 2003 Dec; 2(12):1361-8. PubMed ID: 14707277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early detection of radiation therapy response in non-Hodgkin's lymphoma xenografts by in vivo 1H magnetic resonance spectroscopy and imaging.
    Lee SC; Poptani H; Pickup S; Jenkins WT; Kim S; Koch CJ; Delikatny EJ; Glickson JD
    NMR Biomed; 2010 Jul; 23(6):624-32. PubMed ID: 20661875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. I-kappa-kinase-2 (IKK-2) inhibition potentiates vincristine cytotoxicity in non-Hodgkin's lymphoma.
    Al-Katib A; Arnold AA; Aboukameel A; Sosin A; Smith P; Mohamed AN; Beck FW; Mohammad RM
    Mol Cancer; 2010 Sep; 9():228. PubMed ID: 20809973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cell cycle and apoptosis regulatory protein (CARP)-1 is a novel, adriamycin-inducible, diffuse large B-cell lymphoma (DLBL) growth suppressor.
    Levi E; Zhang L; Aboukameel A; Rishi S; Mohammad RM; Polin L; Hatfield JS; Rishi AK
    Cancer Chemother Pharmacol; 2011 Jun; 67(6):1401-13. PubMed ID: 20809119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mapping the redox state of CHOP-treated non-Hodgkin's lymphoma xenografts in mice.
    Xu HN; Mir TA; Lee SC; Feng M; Farhad N; Choe R; Glickson JD; Li LZ
    Adv Exp Med Biol; 2013; 789():243-249. PubMed ID: 23852501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical studies of TW-37, a new nonpeptidic small-molecule inhibitor of Bcl-2, in diffuse large cell lymphoma xenograft model reveal drug action on both Bcl-2 and Mcl-1.
    Mohammad RM; Goustin AS; Aboukameel A; Chen B; Banerjee S; Wang G; Nikolovska-Coleska Z; Wang S; Al-Katib A
    Clin Cancer Res; 2007 Apr; 13(7):2226-35. PubMed ID: 17404107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Plosker GL; Figgitt DP
    Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical studies of a nonpeptidic small-molecule inhibitor of Bcl-2 and Bcl-X(L) [(-)-gossypol] against diffuse large cell lymphoma.
    Mohammad RM; Wang S; Aboukameel A; Chen B; Wu X; Chen J; Al-Katib A
    Mol Cancer Ther; 2005 Jan; 4(1):13-21. PubMed ID: 15657349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bryostatin 1 down-regulates mdr1 and potentiates vincristine cytotoxicity in diffuse large cell lymphoma xenografts.
    Al-Katib AM; Smith MR; Kamanda WS; Pettit GR; Hamdan M; Mohamed AN; Chelladurai B; Mohammad RM
    Clin Cancer Res; 1998 May; 4(5):1305-14. PubMed ID: 9607591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monitoring response to chemotherapy of non-Hodgkin's lymphoma xenografts by T(2)-weighted and diffusion-weighted MRI.
    Huang MQ; Pickup S; Nelson DS; Qiao H; Xu HN; Li LZ; Zhou R; Delikatny EJ; Poptani H; Glickson JD
    NMR Biomed; 2008 Nov; 21(10):1021-9. PubMed ID: 18988250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lactate imaging with Hadamard-encoded slice-selective multiple quantum coherence chemical-shift imaging.
    Pickup S; Lee SC; Mancuso A; Glickson JD
    Magn Reson Med; 2008 Aug; 60(2):299-305. PubMed ID: 18666110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Comparison the efficacy and prognosis of different first-line treatment for elderly diffuse large B-cell lymphoma].
    Liu P; Jiang SY; He XH; Qin Y; Gui L; Zhou SY; Yang JL; Yang S; Wen TY; Shi YK
    Zhonghua Zhong Liu Za Zhi; 2020 Mar; 42(3):234-241. PubMed ID: 32252203
    [No Abstract]   [Full Text] [Related]  

  • 19. Practicability and acute haematological toxicity of 2- and 3-weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin's lymphoma: results from the NHL-B trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).
    Wunderlich A; Kloess M; Reiser M; Rudolph C; Truemper L; Bittner S; Schmalenberg H; Schmits R; Pfreundschuh M; Loeffler M;
    Ann Oncol; 2003 Jun; 14(6):881-93. PubMed ID: 12796026
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anemia as a useful biomarker in patients with diffuse large B-cell lymphoma treated with R-CHOP immunochemotherapy.
    Hong J; Woo HS; Kim H; Ahn HK; Sym SJ; Park J; Ahn JY; Cho EK; Shin DB; Lee JH
    Cancer Sci; 2014 Dec; 105(12):1569-75. PubMed ID: 25263825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.